ANGI-2 Identification and functions of CD44 as a predictor for bevacizumab-resistant glioblastoma to optimally treat the tumor with bevacizumab

Anti-angiogenic therapy with bevacizumab (Bev), a monoclonal antibody targeting vascular endothelial growth factor (VEGF), is a common treatment for recurrent glioblastoma (GBM), but its survival benefit is limited. Resistance to Bev is thought to be a major cause of ineffectiveness on Bev therapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Akihiro, Nishikawa, Masahiro, Ohnishi, Takanori, Yano, Hajime, Ohtsuka, Yoshihiro, Suehiro, Satoshi, Yamashita, Daisuke, Watanabe, Hideaki, Tanaka, Junya, Kunieda, Takeharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Supplement Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648247/
http://dx.doi.org/10.1093/noajnl/vdab159.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648247/
http://dx.doi.org/10.1093/noajnl/vdab159.004

Ejemplares similares